ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2020-09-24 20:00 |
Abivax presents first-half 2020 financial results and operations update (news w…
|
English | HTML • 34.7 KB | ||
| 2020-09-15 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | PDF • 277.0 KB | ||
| 2020-09-02 21:00 |
Abivax presente des resultats cliniques a long terme sur l'efficacité et la tol…
|
French | PDF • 410.5 KB | ||
| 2020-09-02 21:00 |
ABIVAX: Abivax reports long-lasting two-year efficacy and safety data from ABX4…
|
English | HTML • 15.7 KB | ||
| 2020-09-02 18:00 |
Abivax : Nombre d'actions composant le capital social et nombre total de droits…
|
French | PDF • 275.4 KB | ||
| 2020-07-21 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | PDF • 276.4 KB | ||
| 2020-07-21 18:00 |
ABIVAX: Bilan semestriel du contrat de liquidité au 30 juin 2020.
|
French | PDF • 229.5 KB | ||
| 2020-07-02 07:30 |
Abivax traite un premier patient dans l'essai de Phase 2b/3 d'ABX464 dans le Co…
|
French | PDF • 247.1 KB | ||
| 2020-07-02 07:30 |
Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
|
English | HTML • 16.7 KB | ||
| 2020-06-30 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | PDF • 276.4 KB | ||
| 2020-06-22 19:20 |
Abivax provides business update on most recent achievements and announces posit…
|
English | HTML • 15.4 KB | ||
| 2020-06-22 19:18 |
Informations privilégiées / Autres communiqués
|
French | PDF • 253.5 KB | ||
| 2020-06-15 18:02 |
ABIVAX: Abivax receives 5m non-dilutive financing from Societe Generale as Sta…
|
English | HTML • 10.8 KB | ||
| 2020-05-25 18:17 |
Rapports financiers et d'audit annuels / Rapport financier annuel
|
French | PDF • 3.8 MB | ||
| 2020-05-25 18:00 |
Abivax publishes universal registration document 2020 'Document d'Enregistremen…
|
English | HTML • 6.9 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
